{"id":"convalescent-anti-sars-cov-2-mbt-plasma","safety":{"commonSideEffects":[{"rate":"null","effect":"Injection site reactions"},{"rate":"null","effect":"Fever"},{"rate":"null","effect":"Headache"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"This treatment involves the administration of antibodies that have been shown to be effective against SARS-CoV-2, which can help to neutralize the virus and reduce the severity of symptoms. The antibodies are derived from the plasma of recovered patients, which contains a high concentration of these beneficial antibodies.","oneSentence":"Convalescent anti-SARS-CoV-2 MBT plasma is a treatment that uses antibodies from recovered COVID-19 patients to help the body fight the virus.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T03:28:36.774Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Treatment of COVID-19"}]},"trialDetails":[{"nctId":"NCT04621123","phase":"PHASE2","title":"Plasma for Early Treatment in Non-hospitalised Mild or Moderate COVID-19 Patients","status":"COMPLETED","sponsor":"Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia","startDate":"2020-11-10","conditions":"SARS-CoV-2 Infection, Safety and Efficacy","enrollment":384},{"nctId":"NCT04547127","phase":"PHASE2","title":"A Study to Evaluate Safety and Efficacy of Convalescent Methylene Blue Treated (MBT) Plasma From Donors Recovered From Coronavirus Disease 2019 (COVID-19)","status":"COMPLETED","sponsor":"Instituto Grifols, S.A.","startDate":"2020-04-29","conditions":"COVID-19","enrollment":200}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"Convalescent anti-SARS-CoV-2 MBT plasma","genericName":"Convalescent anti-SARS-CoV-2 MBT plasma","companyName":"Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia","companyId":"fundaci-n-fls-de-lucha-contra-el-sida-las-enfermedades-infecciosas-y-la-promoci","modality":"Biologic","firstApprovalDate":"","aiSummary":"Convalescent anti-SARS-CoV-2 MBT plasma is a treatment that uses antibodies from recovered COVID-19 patients to help the body fight the virus. Used for Treatment of COVID-19.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}